Scholar Rock Holding (SRRK) Long-Term Debt Repayments (2025 - 2026)
Scholar Rock Holding's (SRRK) quarterly Long-Term Debt Repayments came in at $103.1 million in Q1 2026, up 303.83% year-on-year from $25.5 million in Q1 2025, and up 303.83% quarter-over-quarter from $25.5 million in Q1 2025.
Scholar Rock Holding (SRRK) Long-Term Debt Repayments (2025 - 2026) Analysis & Trends
Scholar Rock Holding's Long-Term Debt Repayments history runs 2 years deep, the most recent figure standing at $103.1 million for Q1 2026.
- On a quarterly basis, Long-Term Debt Repayments rose 303.83% year-over-year to $103.1 million in Q1 2026; TTM through Mar 2026 was $103.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $25.5 million, changed N/A from the prior year.
- Long-Term Debt Repayments advanced to $103.1 million in Q1 2026 per SRRK's latest filing, from $25.5 million in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $103.1 million in Q1 2026 and bottomed at $25.5 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.64 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - | 103.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 103.06 Mn |
| Mar 31, 2026 | 103.06 Mn |
| Mar 31, 2025 | 25.52 Mn |
| Mar 31, 2025 | 25.52 Mn |